Serina Therapeutics director buys 12,183 shares
Serina Therapeutics director Marshall Richard Peter bought 12,183 shares of common stock in an open-market transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Serina Therapeutics director Marshall Richard Peter bought 12,183 shares of common stock in an open-market transaction. The purchase occurred on May 19, 2026 at a weighted average price of $1.65 per share, with trade prices ranging from $1.59 to $1.73. Following this transaction, he directly holds 12,183 shares of Serina Therapeutics common stock.
Insider Trade Summary
Net Buyer: 12,183 shares
Net Buy
1 txn
Insider
Marshall Richard Peter
Role
Director
Bought
12,183 shs ($20K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 12,183 | $1.65 | $20K |
Holdings After Transaction:
Common Stock — 12,183 shares (Direct)
Footnotes (1)
- F1. The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.59 per share to a high purchase price of $1.73 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.
Key Figures
Shares purchased: 12,183 shares
Weighted average price: $1.65 per share
Price range: $1.59–$1.73 per share
+1 more
4 metrics
Shares purchased
12,183 shares
Open-market purchase on May 19, 2026
Weighted average price
$1.65 per share
Average of multiple trades on May 19, 2026
Price range
$1.59–$1.73 per share
Range of individual trade prices in the purchase
Shares owned after
12,183 shares
Direct holdings following the reported transaction
Key Terms
open-market purchase, weighted average purchase price, Common Stock, Form 4
4 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"The price reflects the weighted average purchase price of multiple transactions"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Serina Therapeutics (SER) report?
Serina Therapeutics reported that director Marshall Richard Peter bought 12,183 shares of common stock. The open-market purchase was made at a weighted average price of $1.65 per share, indicating a direct increase in his personal holdings of Serina’s stock.
When did the Serina Therapeutics (SER) insider purchase take place?
The insider purchase took place on May 19, 2026. On that date, director Marshall Richard Peter executed multiple open-market trades in Serina Therapeutics common stock, which together resulted in a weighted average purchase price of $1.65 per share.
What are Marshall Richard Peter’s Serina Therapeutics (SER) holdings after the trade?
After the reported transaction, Marshall Richard Peter directly owns 12,183 shares of Serina Therapeutics common stock. This post-transaction figure matches the total number of shares purchased in the filing, indicating his full reported stake in this Form 4.
Was the Serina Therapeutics (SER) insider trade a market purchase or another type?
The transaction was an open-market purchase of common stock. The Form 4 identifies it with code “P,” meaning a purchase in the open market or private transaction, and classifies the shares as directly owned by the reporting director after the trade.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates